Arvinas (ARVN) Current Deferred Revenue (2017 - 2026)
Arvinas (ARVN) recorded quarterly Current Deferred Revenue of $190.0 million in Q1 2026, down 7.59% quarter-over-quarter from $205.6 million in Q4 2025, and down 26.75% on a YoY basis from $259.4 million in Q1 2025.
Arvinas (ARVN) Current Deferred Revenue (2017 - 2026) Analysis & Trends
Arvinas' Current Deferred Revenue history runs 10 years deep, the most recent figure standing at $190.0 million for Q1 2026.
- In Q1 2026, Current Deferred Revenue fell 26.75% year-over-year to $190.0 million; the TTM figure through Mar 2026 stood at $190.0 million (down 26.75% YoY), while the FY2025 annual figure was $205.6 million, down 54.13% from the prior year.
- Current Deferred Revenue was $190.0 million for Q1 2026 at Arvinas, down from $205.6 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $719.4 million in Q1 2022 to a low of $102.9 million in Q2 2025.
- Historically, Current Deferred Revenue has averaged $466.3 million across 5 years, with a median of $523.9 million in 2024.
- The sharpest annual moves came in 2022 and 2025: Current Deferred Revenue soared 1759.46% in 2022, then slumped 82.83% in 2025.
- A 5-year view of Current Deferred Revenue shows it stood at $623.7 million in 2022, then fell by 11.94% to $549.2 million in 2023, then retreated by 18.39% to $448.2 million in 2024, then sank by 54.13% to $205.6 million in 2025, then retreated by 7.59% to $190.0 million in 2026.
- The last three Current Deferred Revenue figures came in at $190.0 million (Q1 2026), $205.6 million (Q4 2025), and $215.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Arvinas | 492.16 Mn | -122.74 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 190.00 Mn |
| Dec 31, 2025 | 205.60 Mn |
| Sep 30, 2025 | 215.10 Mn |
| Jun 30, 2025 | 102.90 Mn |
| Mar 31, 2025 | 259.40 Mn |
| Dec 31, 2024 | 448.20 Mn |
| Sep 30, 2024 | 503.70 Mn |
| Jun 30, 2024 | 599.20 Mn |
| Mar 31, 2024 | 523.90 Mn |
| Dec 31, 2023 | 549.20 Mn |
| Sep 30, 2023 | 506.10 Mn |
| Jun 30, 2023 | 540.60 Mn |
| Mar 31, 2023 | 593.80 Mn |
| Dec 31, 2022 | 623.70 Mn |
| Sep 30, 2022 | 657.70 Mn |
| Jun 30, 2022 | 688.00 Mn |
| Mar 31, 2022 | 719.40 Mn |
| Dec 31, 2021 | 740.50 Mn |
| Sep 30, 2021 | 763.40 Mn |
| Jun 30, 2021 | 37.00 Mn |